Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZBEAM2: Zevalin with BEAM and ASCT in DLBCL
NCT00689169Phase 2
Key facts
- Status
- Completed
- Start
- Aug 2007
- Primary completion
- Jan 2011
- Countries
- 1
- Sponsor
- Lymphoma Study Association
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Drugs
- ibritumomab tiuxetan
- Conditions
- diffuse large B-cell lymphoma (DLBCL)
01
Overview
Phase 2, open-label, single-arm trial of ibritumomab tiuxetan in diffuse large B-cell lymphoma (DLBCL), sponsored by Lymphoma Study Association. Primary endpoint: Event Free Survival at 2 years. Started Aug 2007; status: completed.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
Experimental
ZBEAM (Zevalin, BCNU, Etoposide, Aracytine, Melphalan) + ASCT + Rituximab
03
Who it enrols
Patients aged 18-65 with CD20+ DLBCL, IPI > 1, in CR or PR after first-line rituximab-containing chemotherapy, eligible for ASCT.
04
Endpoints
Primary
Event Free Survival
Secondary
Overall Response Rate
Beyond the preview
Go deeper on NCT00689169.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00689169.